Drug Shortage Report for HAVRIX 1440

Last updated on 2025-05-29

Report ID 254935
Drug Identification Number 02187078
Brand name HAVRIX 1440
Common or Proper name hepatitis A vaccine, inactivated
Company Name GLAXOSMITHKLINE INC
Market Status MARKETED
Active Ingredient(s) HEPATITIS A VIRUS, INACTIVATED
Strength(s) 1440UNIT
Dosage form(s) SUSPENSION
Route of administration INTRAMUSCULAR INTRAMUSCULAR
Packaging size 1's (prefilled syringe / seringue préremplie)
Anatomical Therapeutical Chemical (ATC) code J07BC
Anatomical Therapeutical Chemical (ATC) description VIRAL VACCINES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2025-04-09
Estimated end date 2025-05-30
Actual end date 2025-05-27
Shortage status Resolved
Updated date 2025-05-29
Company comments Doses reserved for Public programs, supply disruptions may be seen in the private market.
Health Canada comments
Tier 3 Status No
Company contact information 1-800-387-7374

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v8 2025-05-29 French Compare
v7 2025-05-29 English Compare
v6 2025-05-16 French Compare
v5 2025-05-16 English Compare
v4 2025-05-02 French Compare
v3 2025-05-02 English Compare
v2 2025-04-11 French Compare
v1 2025-04-11 English Compare

Showing 1 to 8 of 8